CTOs on the Move

MBX Biosciences

www.mbxbio.com

 
MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.mbxbio.com
  • 11711 N. Meridian Street Suite 310
    Carmel, IN USA 46032
  • Phone: N/A

Executives

Name Title Contact Details

Funding

MBX Biosciences raised $34.6M on 07/27/2020

Similar Companies

Treasure Coast Radiation Oncology, Pa

Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armune

Armune BioScience, Inc. develops and commercializes molecular diagnostic and prognostic tests for prostate, lung, and breast cancers that will allow physicians and patients to make more personalized treatment decisions. The company was founded by members of the Apjohn Group, LLC, a business accelerator that brings together valuable resources of management talent and angel/seed financing. The company’s corporate headquarters are in Kalamazoo, MI and the laboratory is in Ann Arbor, MI.

Avidity Biosciences

Avidity Biosciences, Inc.`s mission is to profoundly improve people`s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity`s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity`s advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA.

ZyStor Therapeutics

ZyStor Therapeutics is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NaturalNano Inc

NaturalNano Inc is a Pittsford, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.